Metabolic Category
GDF-8 (Myostatin)
THE MUSCLE REGULATOR
Growth Differentiation Factor 8; MSTN
Myostatin (GDF-8) is your body's natural limiter on muscle growth. It tells muscles "that's enough" and prevents them from getting too large. Animals and rare humans born without myostatin develop extraordinary muscle mass. Myostatin inhibitors (not myostatin itself) are what people use to block this signal and unlock muscle growth.
GDF-8 (Myostatin) Evidence Snapshot
How these guides are reviewed- Regulatory status
- Not FDA approved · research use only
- Dosing guidance
- Reviewed by our clinical team
- Linked evidence
- 6 research sources
- Content updated
- May 8, 2026
Dose and schedule recommendations shown below come from The Peptide App Clinical Team. Research links are provided so readers can inspect the supporting evidence directly. Review the sources.
Quick Answers About GDF-8 (Myostatin)
Is GDF-8 (Myostatin) FDA approved?
No. This profile records GDF-8 (Myostatin) as not FDA approved and for research use only.
More context
Review the regulatory and source details on this page for the current context.
What dose does The Peptide App Clinical Team recommend for GDF-8 (Myostatin)?
Dose: Inhibitors vary - no standard myostatin protocol.
More context
Schedule: daily. Cycle: Varies by inhibitor type. This is clinical-team guidance for reference and does not replace individualized instructions from a licensed clinician.
What research supports this GDF-8 (Myostatin) guide?
This guide links to 6 curated or current research sources.
More context
Open the research section to inspect the source titles, publication details, study types, and available abstracts directly.
Review the GDF-8 (Myostatin) research sourcesStudied Effects & Mechanisms
Muscle Limiter
Myostatin naturally prevents excessive muscle growth
TGF-β Signaling
Acts through Smad pathway to suppress muscle genes
Inhibition = Growth
Blocking myostatin removes the brake on muscle
Clinical & Research Context
People researching myostatin inhibition · Those with muscle-wasting conditions · Bodybuilders seeking muscle growth · Anyone studying muscle physiology · Researchers developing myostatin blockers
Research-Market Price Snapshot
A compact market signal for this profile. The dedicated pricing page owns vendor, vial-size, and price-per-mg comparisons.
Updated Jul 16, 2026
- Vendors
- 1
- Listings
- 1
- Observed range
- $199–$199
GDF-8 (Myostatin) Research
Live PubMed intelligence from the research crawler
Age-related changes in craniofacial morphology in GDF-8 (myostatin)-deficient mice.
Anatomical record (Hoboken, N.J. : 2007) · Jan 1, 2010
It is well recognized that masticatory muscle function helps determine morphology, although the extent of function on final form is still debated. GDF-8 (myostatin), a transcription factor is a negative regulator of skeletal muscle growth. A recent study has shown that mice homozygous for the myostatin mutation had increased muscle mass and craniofacial dysmorphology in adulthood. However, it is unclear whether such dysmorphology is present at birth. This study examines the onset and relationship between hypermuscularity and craniofacial morphology in neonatal and adult mice with GDF-8 deficiency. Fifteen (8 wild-type and 7 GDF-8 -/-), 1-day-old and 16 (9 wt and 7 GDF-8 -/-), 180-day-old male CD-1 mice were used. Standardized radiographs were taken of each head, scanned, traced, and cephalometric landmarks identified. Significant mean differences were assessed using a group x age, two-way ANOVA. Myostatin-deficient mice had significantly (P < 0.01) smaller body and masseter muscle weights and craniofacial skeletons at 1 day of age and significantly greater body and masseter muscle weights at 180 days of age compared to controls. Myostatin-deficient mice showed significantly (P < 0.001) longer and "rocker-shaped" mandibles and shorter and wider crania compared to controls at 180 days. Significant correlations were noted between masseter muscle weight and all cephalometric measurements in 180-day-old Myostatin-deficient mice. Results suggest that in this mouse model, there may be both early systemic skeletal growth deficiencies and later compensatory changes from hypermuscularity. These findings reiterate the role that masticatory muscle function plays on the ontogeny of the cranial vault, base, and most notably the mandible.
Bone architecture and disc degeneration in the lumbar spine of mice lacking GDF-8 (myostatin).
Journal of orthopaedic research : official publication of the Orthopaedic Research Society · Nov 1, 2003
GDF-8, also known as myostatin, is a member of the transforming growth factor-beta superfamily of secreted growth and differentiation factors that is expressed in vertebrate skeletal muscle. Myostatin functions as a negative regulator of skeletal muscle growth and myostatin null mice show a doubling of muscle mass compared to normal mice. We describe here morphology of the lumbar spine in myostatin knockout (Mstn(-/-)) mice using histological and densitometric techniques. The Mstn(-/-) mice examined in this study weigh approximately 10% more than controls (p<0.001) but the iliopsoas muscle is over 50% larger in the knockout mice than in wild-type mice (p<0.001). Peripheral quantitative computed tomography (pQCT) data from the fifth lumbar vertebra show that mice lacking myostatin have approximately 50% greater trabecular bone mineral density (p=0.001) and significantly greater cortical bone mineral content than normal mice. Toluidine blue staining of the intervertebral disc between L4-L5 reveals loss of proteoglycan staining in the hyaline end plates and inner annulus fibrosus of the knockout mice. Loss of cartilage staining in the caudal end plate of L4 is due to ossification of the end plate in the myostatin-deficient animals. Results from this study suggest that increased muscle mass in mice lacking myostatin is associated with increased bone mass as well as degenerative changes in the intervertebral disc.
Low Myostatin Serum Levels Are Associated with Poor Outcome in Critically Ill Patients.
Diagnostics (Basel, Switzerland) · Aug 8, 2020
Background: Growth differentiation factor 8, GDF-8 (Myostatin), is a protein released by myocytes inhibiting muscle growth and differentiation. Serum concentrations of Myostatin can predict poor survival in different chronic diseases, but its role in critical illness and sepsis is obscure. Our aim was to investigate Myostatin levels as a potential prognostic biomarker in critically ill patients with sepsis. Methods: We therefore measured Myostatin serum concentrations in 165 critically ill patients (106 with sepsis, 59 without sepsis) upon admission to the medical intensive care unit (ICU), in comparison to 14 healthy controls. Results: Myostatin levels were significantly decreased in ICU patients compared to controls but did not differ in patients with or without sepsis. However, Myostatin concentrations were significantly lower in patients requiring mechanical ventilation and indicated a trend towards dependency of intravenous vasopressors. Interestingly, we observed a negative correlation between Myostatin levels and markers of systemic inflammation. Strikingly, overall survival (OS) was significantly impaired in patients with low Myostatin levels in all critically ill patients. Low Myostatin levels at baseline turned out as an independent prognostic marker for OS in multivariate Cox-regression analysis (HR: 0.433, 95% CI: 0.211-0.889, p = 0.023). Conclusions: In summary, serum Myostatin concentrations are significantly decreased in critically ill patients and associated with disease severity. Low Myostatin levels also identify a subgroup of ICU patients that are more likely to face an unfavorable clinical outcome in terms of OS.
Muscle proteolysis via ubiquitin-proteasome system (UPS) is activated by BthTx-I Lys49 PLA2 but not by BthTx-II Asp49 PLA2 and Bothrops jararacussu venom.
Toxicology and applied pharmacology · Sep 1, 2020
Bites by viperid snakes belonging to Bothrops genus produce fast and intense local edema, inflammation, bleeding and myonecrosis. In this study, we investigated the role of Myogenic Regulatory Factors (MRFs: MyoD; Myog), negatively regulated by GDF-8 (Myostatin), and ubiquitin-proteasome system pathway (UPS: MuRF-1; Fbx-32) in gastrocnemius muscle regeneration after Bothrops jararacussu snake venom (Bjussu) or its isolated phospholipase A2 myotoxins, BthTx-I (Lys-49 PLA2) and BthTx-II (Asp-49 PLA2) injection. Male Swiss mice received a single intra-gastrocnemius injection of crude Bjussu, at a dose/volume of 0.83 mg/kg/20 μl, and BthTx-I or BthTx-II, at a dose/volume of 2.5 mg/kg/20 μl. Control mice (Sham) received an injection of sterile saline solution (NaCl 0.9%; 20 μl). At 24, 48, 72 and 96 h post injection, right gastrocnemius was collected for protein expression analyses. Based on the temporal expressional dynamics of MyoD, Myog and GDF-8/Myostatin, it was possible to propose that the myogenesis pathway was impacted most badly by BthTx-II followed by BthTx-I and lastly by B. jararacussu venom, thus suggesting that catalytic activity has likely inhibitory role on the satellite cells-mediated reparative myogenesis pathway. Inversely, the catalytic activity seems to be not a determinant for the activation of proteins ubiquitination by MuRF-1 and Fbx-32/Atrogin-1 E3 proteasome ligases, given proteolysis pathway through UPS was activated neither after Bjussu, nor after BthTx-II, but just after the catalytically-inactive BthTx-I Lys-49 PLA2-homologue exposure. The findings of this study disclose interesting perspective for further mechanistic studies about pathways that take part in the atrophy and repair after permanent damage induced by bothropic snakebites.
Craniofacial morphology in myostatin-deficient mice.
Journal of dental research · Nov 1, 2007
GDF-8 (myostatin) is a negative growth regulator of skeletal muscle, and myostatin-deficient mice are hypermuscular. Muscle size and force production are thought to influence growth of the craniofacial skeleton. To test this relationship, we compared masticatory muscle size and craniofacial dimensions in myostatin-deficient and wild-type CD-1 control mice. Myostatin-deficient mice had significantly (p < 0.01) greater body (by 18%) and masseter muscle weight (by 83%), compared with wild-type controls. Significant differences (p < 0.05) were noted for cranial vault length, maxillary length, mandibular body length, and mandibular shape index. Significant correlations were noted between masseter muscle weight and mandibular body length (r = 0.68; p < 0.01), cranial vault length (r = -0.57; p < 0.05), and the mandibular shape index (r = -0.56; p < 0.05). Masticatory hypermuscularity resulted in significantly altered craniofacial morphology, probably through altered biomechanical stress. These findings emphasize the important role that masticatory muscle function plays in the ontogeny of the cranial vault, the maxilla, and, most notably, the mandible.
Research references
Related Peptides
IGF-LR3
THE MUSCLE MAXIMIZERCModerateMetabolic Modulator · Growth Hormone & Musculoskeletal SupportMetabolic · Metabolic ModulatorDoseSee guide↻Cycle4-6 weeks on, 4 weeks off◷Kicks inMuscle fullness and recovery improvements...Extended-release IGF-1 for powerful muscle growth
from $30.10/mg · 53 vendorsNº 003 / 0065-Amino-1MQ
THE FAT BURNERBGoodMetabolic Modulator · Weight ManagementMetabolic · Metabolic ModulatorDose150 mcg↻Cycle3 weeks on, 1 week off◷Kicks inMost users notice energy improvements within...Boost metabolism and burn fat without changing your diet
from $0.68/mg · 69 vendorsNº 001 / 006CJC-1295 (no DAC)
THE GH SUSTAINERBGoodGrowth Hormone & Musculoskeletal Support · Anti-Aging & LongevityHealing · Growth Hormone & Musculoskeletal SupportDose100 mcg↻Cycle8 weeks on, 8 weeks off◷Kicks inSleep improvements within 1-2 weeks; body...Long-acting growth hormone releaser for muscle, recovery and anti-aging
from $3/mg · 74 vendorsNº 002 / 006Ipamorelin
THE AMPLIFIERAHighGrowth Hormone & Musculoskeletal Support · Anti-Aging & LongevityHealing · Growth Hormone & Musculoskeletal SupportDose200 mcg↻Cycle8-12 weeks on, 4 weeks off◷Kicks inSleep improvements within days; body...Pure growth hormone boost without the unwanted side effects.
from $2.70/mg · 79 vendorsNº 004 / 006MOTS-c
THE METABOLIC MESSENGERBGoodMetabolic Modulator · Mitochondrial SupportMetabolic · Metabolic ModulatorDose5 mg↻Cycle8-12 weeks on, 4 weeks off◷Kicks inMetabolic improvements may be measurable...Exercise in a peptide - boost metabolism without the treadmill
from $0.75/mg · 110 vendorsNº 005 / 006NAD+
THE ENERGIZERBGoodMetabolic Modulator · Mitochondrial SupportHealing · Metabolic ModulatorDose50 mg↻Cycle8 weeks on, 8 weeks off (for injections)◷Kicks inEnergy improvements often noticed within the...Get back the energy and mental clarity you had at 25.
from $0.03/mg · 62 vendorsNº 006 / 006